Activities of the Triazole Derivative SCH 56592 (Posaconazole) against Drug-Resistant Strains of the Protozoan ParasiteTrypanosoma (Schizotrypanum) cruzi in Immunocompetent and Immunosuppressed Murine Hosts

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Antimicrobial Agents and Chemotherapy

• Publication date

  2000-01-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1128/AAC.44.1.150-155.2000PMID 10602737PMCID PMC89642
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Comparison of a New Triazole Antifungal Agent, Schering 56592, with Itraconazole and Amphotericin B for Treatment of Histoplasmosis in Immunocompetent Mice

  1999cited by this paper
• Chemotherapy of Chagas’ disease: the how and the why

  1999cited by this paper
• Treatment of Murine Fusariosis with SCH 56592

  1999cited by this paper
• Induction of Resistance to Azole Drugs inTrypanosoma cruzi

  1998cited by this paper
• Antiproliferative Effects and Mechanism of Action of SCH 56592 against Trypanosoma (Schizotrypanum)cruzi: In Vitro and In Vivo Studies

  1998influential reference
• In-vitro antiproliferative effects and mechanism of action of the bis-triazole D0870 and its S(-) enantiomer against Trypanosoma cruzi.

  1998cited by this paper
• Interleukin-12 Enhances In Vivo Parasiticidal Effect of Benznidazole during Acute Experimental Infection with a Naturally Drug-Resistant Strain of Trypanosoma cruzi

  1998cited by this paper
• Activity of SCH 56592 compared with those of fluconazole and itraconazole against Candida spp

  1997cited by this paper
• Identification of an Ixodes ricinus salivary gland fraction through its ability to stimulate CD4 T cells present in BALB/c mice lymph nodes draining the tick fixation site

  1997cited by this paper
• Efficacy of SCH-56592 in a temporarily neutropenic murine model of invasive aspergillosis with an itraconazole-susceptible and an itraconazole-resistant isolate of Aspergillus fumigatus

  1997cited by this paper
• Immunological control of Trypanosoma cruzi infection and pathogenesis of Chagas' disease.

  1997cited by this paper
• Chemotherapy of human leishmaniasis and trypanosomiasis.

  1997cited by this paper
• Activity of a new triazole, Sch 56592, compared with those of four other antifungal agents tested against clinical isolates of Candida spp. and Saccharomyces cerevisiae

  1997cited by this paper
• Lipid biosynthesis pathways as chemotherapeutic targets in kinetoplastid parasites

  1997cited by this paper
• Activity of the triazole SCH 56592 against disseminated murine coccidioidomycosis

  1997cited by this paper
• Antiproliferative Effects of △24(25) Sterol Methyl Transferase Inhibitors on Trypanosoma (Schizotrypanum) cruzi: In vitro and in vivo Studies

  1996cited by this paper
• Recrudescence induced by cyclophosphamide of chronic Trypanosoma cruzi infection in mice is influenced by the parasite strain.

  1996cited by this paper
• In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans

  1996cited by this paper
• In vitro and in vivo activities of SCH 56592 against Blastomyces dermatitidis

  1996cited by this paper
• Antiproliferative effects of delta 24(25) sterol methyl transferase inhibitors on Trypanosoma (Schizotrypanum) cruzi: in vitro and in vivo studies.

  1996cited by this paper
• Cure of Short- and Long-Term Experimental Chagas' Disease Using D0870

  1996cited by this paper
• Modification of the sterol composition of Trypanosoma (Schizotrypanum) cruzi epimastigotes by delta 24(25)-sterol methyl transferase inhibitors and their combinations with ketoconazole.

  1995cited by this paper
• Flow cytometry, a new approach to detect anti-live trypomastigote antibodies and monitor the efficacy of specific treatment in human Chagas' disease

  1995cited by this paper
• Pathology of patients with Chagas' disease and acquired immunodeficiency syndrome.

  1994cited by this paper
• Mevinolin (lovastatin) potentiates the antiproliferative effects of ketoconazole and terbinafine against Trypanosoma (Schizotrypanum) cruzi: in vitro and in vivo studies

  1993cited by this paper
• An experimental and clinical assay with ketoconazole in the treatment of Chagas disease.

  1993cited by this paper
• Experimental chemotherapy with combinations of ergosterol biosynthesis inhibitors in murine models of Chagas' disease

  1993cited by this paper
• The challenge of Chagas' disease chemotherapy: an update of drugs assayed against Trypanosoma cruzi.

  1993cited by this paper
• Avaliação da atividade terapêutica do itraconazol nas infecções crônicas, experimental e humana, pelo Trypanosoma cruzi

  1992cited by this paper
• [Evaluation of the therapeutic activity of itraconazole in chronic infections, experimental and human, by Trypanosoma cruzi].

  1992cited by this paper
• Antiproliferative synergism of the allylamine SF 86-327 and ketoconazole on epimastigotes and amastigotes of Trypanosoma (Schizotrypanum) cruzi

  1988cited by this paper
• Failure of ketoconazole to cure chronic murine Chagas' disease.

  1988cited by this paper
• Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chagas disease.

  1987cited by this paper
• Suggested guidelines for work with live Trypanosoma cruzi.

  1983cited by this paper
• Tratamento da doença de Chagas

  1982cited by this paper
• Tratamento da doença de Chagas

  1982cited by this paper

• Design, Synthesis, and Trypanosomicidal Evaluation of Eugenol-Based Azole Hybrids: Discovery of an In Vitro Active and Selective Compound

  2025cites this paper
• Chagas Disease in a Non-Endemic Setting: Clinical Profile, Treatment Outcomes, and Predictors of Cure in a 15-Year Cohort Study

  2025cites this paper
• Anti-trypanosomal quinazolines targeting lysyl-tRNA synthetases show partial efficacy in a mouse model of acute Chagas disease

  2025cites this paper
• Progress and Prospects of Triazoles in Advanced Therapies for Parasitic Diseases

  2025cites this paper
• Dissimilar Trypanosoma cruzi genotype-specific serological profile assessed by Chagas-Flow ATE IgG1 upon benznidazole etiological treatment of chronic Chagas disease

  2024cites this paper
• N-substituted-4-(pyridin-4-ylalkyl)piperazine-1-carboxamides and related compounds as Leishmania CYP51 and CYP5122A1 inhibitors.

  2024cites this paper
• Biosynthesis of ergosterol as a relevant molecular target of metal-based antiparasitic and antifungal compounds

  2024cites this paper
• Tackling the Challenges of human Chagas Disease: a Comprehensive Review of Treatment Strategies in the Chronic Phase and Emerging Therapeutic Approaches.

  2024cites this paper
• Trypanosoma cruzi antigen detection in blood to assess treatment efficacy and cure in mice models of Chagas disease

  2024cites this paper
• New insights into Trypanosoma cruzi genetic diversity, and its influence on parasite biology and clinical outcomes

  2024cites this paper
• Listen to what the animals say: a systematic review and meta-analysis of sterol 14-demethylase inhibitor efficacy for in vivo models of Trypanosoma cruzi infection

  2024cites this paper
• Synthetic and therapeutic review of triazoles and hybrids

  2024cites this paper
• Fifteen Years after the Definition of Trypanosoma cruzi DTUs: What Have We Learned?

  2023cites this paper
• Clinical trials for Chagas disease: etiological and pathophysiological treatment

  2023cites this paper
• In Vitro and In Silico Evaluations of the Antileishmanial Activities of New Benzimidazole-Triazole Derivatives

  2023cites this paper
• Anti-Trypanosoma cruzi Activity, Mutagenicity, Hepatocytotoxicity and Nitroreductase Enzyme Evaluation of 3-Nitrotriazole, 2-Nitroimidazole and Triazole Derivatives

  2023cites this paper
• Pathogen diversity, immunity, and the fate of infections: lessons learned from Trypanosoma cruzi human-host interactions.

  2022cites this paper
• DRUG ASSOCIATIONS AS ALTERNATIVE AND COMPLEMENTARY THERAPY FOR NEGLECTED TROPICAL DISEASES.

  2021cites this paper
• Antiprotozoal agents: How have they changed over a decade?

  2021cites this paper
• Administration of artinm lectin reduces the severity of the acute phase infection with Trypanosoma cruzi

  2021cites this paper
• Nanomedicines against Chagas disease

  2021cites this paper
• Effect of Posaconazole in an in vitro model of cardiac fibrosis induced by Trypanosoma cruzi.

  2020cites this paper
• Voriconazole-Benznidazole Combination Treatment for Chagas Disease.

  2020cites this paper
• In vitro and in vivo activity of voriconazole and benznidazole combination on trypanosoma cruzi infection models

  2020cites this paper
• Animal models of Chagas disease and their translational value to drug development

  2020cites this paper
• Efficacy of the Benznidazole+Posaconazole combination therapy in parasitemia reduction: An experimental murine model of acute Chagas

  2020cites this paper
• Pharmacological and Cellular Significance of Triazole-Surrogated Compounds

  2020cites this paper
• The current drug discovery landscape for trypanosomiasis and leishmaniasis: Challenges and strategies to identify drug targets

  2020influential citation
• Rationale for Use of Amiodarone and Its Derivatives for Treatment of Chagas' Disease and Leishmaniasis.

  2020cites this paper
• Recent advances on the synthesis of flavans, isoflavans, and neoflavans

  2020cites this paper
• Low-dose of benznidazole promotes therapeutic cure in experimental chronic Chagas' disease with absence of parasitism in blood, heart and colon.

  2020cites this paper
• Planning new Trypanosoma cruzi CYP51 inhibitors using QSAR studies

  2020cites this paper
• Current Approaches of Drug Discovery for Chagas Disease: Methodological Advances.

  2019cites this paper
• In Vitro Benznidazole and Nifurtimox Susceptibility Profile of Trypanosoma cruzi Strains Belonging to Discrete Typing Units TcI, TcII, and TcV

  2019cites this paper
• A case report of long treatment with Itraconazole in a patient with chronic Chagas disease

  2019cites this paper
• Synergic Effect of Allopurinol in Combination with Nitroheterocyclic Compounds against Trypanosoma cruzi

  2019cites this paper
• Trypanocidal and toxicological assessment in vitro and in silico of three sesquiterpene lactones from Asteraceae plant species.

  2019cites this paper
• Planejamento de novos inibidores da CYP51 do Trypanosoma Cruzi por estudos de QSAR

  2019cites this paper
• Parasite, Compartments, and Molecules: Trick versus Treatment on Chagas Disease

  2019cites this paper
• The effect of Benznidazole dose among the efficacy outcome in the murine animal model. A quantitative integration of the literature.

  2019cites this paper
• Response to different benznidazole doses in animal models of chronic phase Chagas disease: a critical review.

  2018cites this paper
• Searching for new drugs for Chagas diseases: triazole analogs display high in vitro activity against Trypanosoma cruzi and low toxicity toward mammalian cells

  2018cites this paper
• Synthesis, biological evaluation and molecular dynamics studies of 1, 2, 4-triazole clubbed Mannich bases

  2018cites this paper
• Drugs and Drug Resistance in African and American Trypanosomiasis

  2018cites this paper
• CYP51 as drug targets for fungi and protozoan parasites: past, present and future

  2018cites this paper
• New Approaches for Chagas’ Disease Chemotherapy

  2018cites this paper
• Polypharmacology in the treatment of Chagas disease.

  2018cites this paper
• Efficacy and Safety of Chagas Disease Drug Therapy and Treatment Perspectives

  2018cites this paper
• Identification of Anti-Trypanosoma cruzi Lead Compounds with Putative Immunomodulatory Activity

  2018cites this paper
• K INETOPLASTIDA : NEW THERAPEUTIC STRATEGIES

  2018cites this paper
• Current advances in drug discovery for Chagas disease.

  2018cites this paper
• Outcome of E1224-Benznidazole Combination Treatment for Infection with a Multidrug-Resistant Trypanosoma cruzi Strain in Mice

  2018cites this paper
• Heme metabolism as a therapeutic target against protozoan parasites

  2018cites this paper
• Genetic Adjuvantation of a Cell-Based Therapeutic Vaccine for Amelioration of Chagasic Cardiomyopathy

  2017cites this paper
• TcVI Trypanosoma cruzi samples from Chagas disease atients with distinct clinical forms and critical analysis of in vitro and n vivo behavior , response to treatment and infection evolution in urine model aykon

  2017cites this paper
• TcI, TcII and TcVI Trypanosoma cruzi samples from Chagas disease patients with distinct clinical forms and critical analysis of in vitro and in vivo behavior, response to treatment and infection evolution in murine model.

  2017cites this paper
• A New Epoch in Antitrypanosomal Treatment for Chagas Disease.

  2017cites this paper
• Cynomolgus macaques naturally infected with Trypanosoma cruzi-I exhibit an overall mixed pro-inflammatory/modulated cytokine signature characteristic of human Chagas disease

  2017cites this paper
• Experimental and Clinical Treatment of Chagas Disease: A Review

  2017cites this paper
• Addressing the Challenges of Chagas Disease: An Emerging Health Concern in the United States.

  2017cites this paper
• Clear Shot at Primary Aim: Susceptibility of Trypanosoma cruzi Organelles, Structures and Molecular Targets to Drug Treatment.

  2017cites this paper
• Biological factors that impinge on Chagas disease drug development

  2017cites this paper
• Defining the targets of antiparasitic compounds.

  2016cites this paper
• Trypanosoma brucei CYP51: Essentiality and Targeting Therapy in an Experimental Model

  2016cites this paper
• Synthesis and biological evaluation of quinolines, thiazolo[3,2-a]pyrimidines, thiadiazolo[3,2-a]pyrimidines and triazolo[3,4-b][1,3,4]thiadiazepines as antimicrobial agents

  2016cites this paper
• Stairway to Heaven or Hell? Perspectives and Limitations of Chagas Disease Chemotherapy.

  2016cites this paper
• Aptamer-Based Detection of Disease Biomarkers in Mouse Models for Chagas Drug Discovery

  2015cites this paper
• Current and Future Chemotherapy for Chagas Disease.

  2015cites this paper
• Translational challenges of animal models in Chagas disease drug development: a review

  2015cites this paper
• Antitrypanosomal Treatment with Benznidazole Is Superior to Posaconazole Regimens in Mouse Models of Chagas Disease

  2015cites this paper
• Chagas Disease Drug Discovery

  2015cites this paper
• Drug Susceptibility of Genetically Engineered Trypanosoma cruzi Strains and Sterile Cure in Animal Models as a Criterion for Potential Clinical Efficacy of Anti-T. cruzi Drugs

  2015cites this paper
• A new era for chagas disease drug discovery?

  2015cites this paper
• Match-making for posaconazole through systems thinking.

  2015cites this paper
• Sterol Biosynthesis Pathway as an Alternative for the Anti-Protozoan Parasite Chemotherapy.

  2015cites this paper
• Effects of artesunate against Trypanosma cruzi.

  2015cites this paper
• The use of posaconazole against Chagas disease

  2015cites this paper
• Potent Inhibitors of the Enzyme Sterol 14α-demethylase AgainstTrypanosoma cruzi

  2014cites this paper
• Nitroheterocyclic compounds are more efficacious than CYP51 inhibitors against Trypanosoma cruzi: implications for Chagas disease drug discovery and development

  2014cites this paper
• Sesquiterpene Lactone in Nanostructured Parenteral Dosage Form Is Efficacious in Experimental Chagas Disease

  2014cites this paper
• 4-Aminopyridyl-Based CYP51 Inhibitors as Anti-Trypanosoma cruzi Drug Leads with Improved Pharmacokinetic Profile and in Vivo Potency

  2014cites this paper
• Membrane therapy for chagas' disease

  2014cites this paper
• Ruthenium Complex with Benznidazole and Nitric Oxide as a New Candidate for the Treatment of Chagas Disease

  2014cites this paper
• Randomized trial of posaconazole and benznidazole for chronic Chagas' disease.

  2014cites this paper
• Drug Strategies Targeting CYP51 in Neglected Tropical Diseases

  2014cites this paper
• Therapeutic responses to different anti-Trypanosoma cruzi drugs in experimental infection by benznidazole-resistant parasite stock

  2014cites this paper
• R-Configuration of 4-Aminopyridyl-Based Inhibitors of CYP51 Confers Superior Efficacy Against Trypanosoma cruzi.

  2014cites this paper
• Estatinas como coadjuvantes nos tratamentos da doença de Chagas e leishmanioses

  2014cites this paper
• Therapeutical approaches under investigation for treatment of Chagas disease

  2014cites this paper
• Selection of molecular targets for drug development against trypanosomatids.

  2014cites this paper
• Potential new clinical therapies for Chagas disease

  2014cites this paper
• Experimental Chagas Disease Parenteral Dosage Form Is Efficacious in Sesquiterpene Lactone in Nanostructured

  2014cites this paper
• Target sites for the design of anti-trypanosomatid drugs based on the structure of dihydroorotate dehydrogenase.

  2013cites this paper
• Complexes of Trypanosoma cruzi Sterol 14α-Demethylase (CYP51) with Two Pyridine-based Drug Candidates for Chagas Disease

  2013cites this paper
• In Vitro and In Vivo Studies of the Antiparasitic Activity of Sterol 14α-Demethylase (CYP51) Inhibitor VNI against Drug-Resistant Strains of Trypanosoma cruzi

  2013cites this paper
• Epidemiology of Chagas disease in Europe: many calculations, little knowledge

  2013cites this paper
• CALRETICULINA DE Trypanosoma cruzi: UN FACTOR DE VIRULENCIA QUE UNIDO EXÓGENAMENTE A EPIMASTIGOTES, PROMUEVE SU PENETRACIÓN A CÉLULAS HOSPEDERAS

  2013cites this paper
• Evaluation of Genotoxic Effects of New Molecules with Possible Trypanocidal Activity for Chagas Disease Treatment

  2013cites this paper
• VNI cures acute and chronic experimental Chagas disease.

  2013cites this paper
• Trypanosoma cruzi Response to Sterol Biosynthesis Inhibitors: Morphophysiological Alterations Leading to Cell Death

  2013cites this paper